Thirteen consecutive fine-needle aspirates of breast carcinoma and five selected breast tumor cell lines were analyzed for ERBB2 and MYC mRNA expression by in situ hybridization. To compare the level of mRNA synthesis with those of gene amplification and oncoprotein synthesis, all tumors were also analyzed by Southern blot analysis, and for ERBBZ also by immunohistochemistry. Expression of ERBB2 mRNA was observed in eight tumors. MYC expression was observed in all tumors studied. Three tumor cell lines expressed both ERBB2 and MYC (SK-BR-3, HeLa, HT-29) and two only MYC (SK-LU-1, HL60). Only one tumor showed amplification of ERBB2 and two of MYC. In all three cases there was a considerable increase in corresponding mRNA synthesis as detected by in situ hybridization. By immunohistochemistry, four cases showed either patchy areas or uniformly distributed, membrane-bound ERBBZ immunoreactivity. All except one case showed increased ERBB2 mRNA synthesis. There was a dear association between the quantity of ERBB2 mRNA and oncoprotein expression. The results show that
Introduction
The ERBB2 proto-oncogene (also known as c-erbB-2, neu, or HER-2) codes for a 181 KD transmembrane glycoprotein with tyrosine kinase activity (I), which is structurally highly homologous to but distinct from the epidermal growth factor (EGF) receptor (2). Activation of the ERBB2 proto-oncogene has been found in many types of carcinoma (3-6) and its amplification or increased expression has been found in about one third of cases of breast carcinoma (7-16). Enhanced expression of ERBB2 is especially associated with invasive ductal carcinomas and comedo-type in situ carcinomas Supported by the Finnish Cultural Fund, the Finnish Anti-Tuberculosis Association, the Finnish Cancer Society, and the University of Oulu, Finland. * Correspondence to: Paavo W O , MD, PhD, Dept. of Pathology, U. of Oulu, Kajaanintie 52 D, 90220 Oulu, Finland. in situ hybridization of fine-needle aspiration material is a sensitive method to detect increased expression of the ERBB2 and MYC oncogenes in breast carcinoma. Furthermore, this study indicates that in a majority of cases some other mechanism than gene amplification appears responsible for the increased gene expression. It is also possible that Southern blot analysis is not a sensitive enough method to detect gene amplifications in the heterogeneous breast tumors, which usually also contain stromal tissue. The fact that not all cases with elevated ERBB2 mRNA synthesis were immunohistochemically positive suggests that either immunohistochemistry (after fmtion with 10% formalin) is a less sensitive method than in situ hybridization to detect abnormal gene expression or that there are cases in which the oncoprotein synthesis is for some reason depressed, even though there is an increase in gene d p t i o n . (]Hstochem C p d e m 1994) KEY WORDS: Oncogenes; Fine-needle biopsy; Breast carcinoma; ERBBZ: MYC. (10, 11, 13) , and its amplification is associated with a poor prognosis (9, 16, 17) and more frequently with Grade 111 ductal carcinomas than with lower-grade carcinomas (8).
The MYC proto-oncogene encodes two nuclear phosphoproteins with molecular weights of 62 KD and 66 KD (18), and its activation is found in benign and malignant proliferating cells. The oncoprotein may function as a transcriptional factor (19). MYC expression is enhanced by several growth-promoting agents such as EGF (20) and is inhibited by transforming growth factor-0 (TGFP) (21) . The cytoplasmic half-life of MYC mRNA transcripts is approximately 30 m h (22). Amplification or increased expression of MYC has been found in many tumors, most notably lymphoid tumors and carcinomas (6, (23) (24) (25) (26) (27) (28) (29) . Its amplification has been found in 6-32% of breast carcinomas and overexpression in (8, 9, 14, 16, 30) . Overexpression of MYC is especially associated with invasive ductal carcinomas (30). Amplification of MYC seems to be an ominous prognostic sign in breast carcinomas (16), along with the classical 7% SOINI, MANNERMAA, WINQVIST, KAMEL, POIKONEN, KMNIEMI, P-6 prognostic indicators such as the presence of lymph node metastases (9), high histological grade (14), and advanced age of the patient (30).
Research conceming these oncogenes has primarily focused on demonstration of structural changes, e.g., by Southern blot techniques (8, 9, 14, 17, 31) , identification of oncogene DNA rearrangement by restriction enzyme analysis (30), analysis of mRNA transcripts by RNAse protection assay (31), demonstration of oncogene expression changes by Northern blot or slot-blot analyses (9, 14, 30) , or immunohistochemical demonstration of the corresponding oncoproteins (10, 11, 13, 32, 33) . The mRNA in situ hybridization method has been used less frequently (15, 31) . Even though in situ hybridization does not reveal the molecular mechanisms behind the overexpression, it does give a good estimate of the amount and location of the transcribed mRNA. Moreover, since the Northern and Southern blot techniques are based on RNA or DNA extraction from the total tissue sample, contamination from other non-tumor cell populations may affect the results.
To study ERBB2 and MYC expression in breast tumors by in situ hybridization, 13 consecutive breast carcinoma samples were analyzed. Instead of using histological sections as in most earlier investigations, we preferred cytological specimens from the tumor tissue. To compare the results with data from other techniques, the results were correlated with those obtained by Southern blot analysis and immunohistochemistry of the tumors. In addition, the results were correlated with known clinical parameters and flow cytometric data. Five tumor cell lines were also analyzed for control purposes. 
Materials and Methods
Fine-needle Aspiration Biopsies. Breast tissues containing tumors and axillary lymph nodes were obtained from surgical operations. The tissue material was received fresh, packed in sterile plastic bags and stored on wet ice. Fine needle aspiration was carried out using a sterile needle (0.7 x 50 mm) and a disposable 10-ml syringe containing approximately 0.5 ml RPMI-1640 (Flow Laboratories; Imine, Scotland) supplemented with 2 mM glutamine. To obtain representative samples, the tumor was aspirated several times and from different areas. The aspirates were suspended in a larger volume of RPMI-1640. The total number of cells was counted and their viability assessed by uypan blue exclusion.
In each case, a fresh sample of about 1 cm3 was removed for flow cytometry and Southern blot analysis, and the remaining tissues were fixed in 10% neuual formalin and embedded in paraffim. The histological sections were stained with hematoxylin-eosin (HE) and periodic acid-Schiff (PAS) for routine histology. Cell Lines. The following human tumor cell lines were obtained from the American Type Culture Collection (ATCC; Rockville, MD) and grown as recommended breast adenocarcinoma (SK-BR-3). which is known to express ERBBZ and shows a four-to eightfold gene amplification (36), promyelocytic leukemia (HG60), which is known to express MYC (37). epithelioid cervical cancer (HeLa), colon adenocarcinoma (HT-29). and adenocarcinoma of the lung (SK-W-1) . C y t q i n preparations ofthe fine-needle aspirates from the breast tumors " IDC, infiltrative duct carcinoma.
Metastases: -, not found; + , found (the number of metastatic lymph nodeslstudicd lymph nodes is shown in parenthesis). Not evaluated.
and axillary lymph nodes and the tumor cell lines were stained with HE and May-Griinwald-Giemsa (MGG) and evaluated by conventional light microscopy.
Preparation of Cytospin Samples for mRNA In Situ Hybridization. Cytocentrifuge preparations (500 rpm, 5 min) (Cytospin 2; Shandon Instruments, Astmoor, UK) were made up from the cell samples using RNAsefree glass slides and applying roughly 50.000-200.000 cells to each slide. The cytospin preparations were briefly dried with an air jet and then fixed for 3 min in a freshly prepared solution of 4% paraformaldehyde (Fluka; Buchs. Switzerland) in PBS, pH 7.2 (all solutions made up in 0.1% diethyl pyrocarbonate-treated water). After fixation, the cytospin preparations were transferred to 70% ethanol at 4'C until used for hybridization (38) (39) (40) (41) . The cell samples were washed twice in 2 x SSC for 1 min each and then acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine, pH 8, for 10 min. They were then rinsed in 2 x SSC, immersed in 0.1 M Tris-HC1 (pH 7) and 0.1 M glycine (pH 7) for 30 min. rinsed again in 2 x SSC, dehydrated through a graded alcohol series, and air-dried (40).
Preparation of RNA Probes for In Situ Hybridization. The specific DNA templates of human ERBB2 and MYC proto-oncogenes for RNA probe synthesis were obtained from NEN Research Products (Boston, MA), catalog numbers NEF532 and NEP-521, respectively. The lengths ofthe RNA probes, as indicated by the manufacturer, are as follows: ERBB2 anti-sense RNA 1630 BP and sense RNA 1570 BP, MYC anti-sense RNA -1000 BP and sense RNA m1470 BP.
Anti-sense and sense RNA probes were generated using either SP6 or T7 RNA polymerase (both from Promega; Madison, WI), together with [ "'SI-UTP (SP6/T7 grade; Amersham International, Amersham, UK). The radioactively labeled RNA probes were purified by centrifugation through Bio-Gel P-30 columns (Bio-Spin 30; Bio-Rad, Richmond, CA). Each invitro transcription reaction yielded RNA probes of high specific activity (typically 4.5-6 x lo8 dpm/0.5 pg DNA template and 50-75% incorporation).
The length and quality of the RNA probes were verified by electrophoresis in agarose gel under denaturing conditions (42) .
In Situ Hybridization of "A.
The hybridization mixture contained the "'S-labeled RNA probe (1.2 x 10' dpmlpl), 50% deionized formamide (BRL; Rockville, MD), 5 mM MT, 500 pg/ml yeast tRNA (BRL), 2 mg/ml bovine serum albumin (BSA) (BRL), and 4 x SSC. The cell samples were hybridized overnight at 50°C while covered with Parafilm (40). washed extensively in 2 x SSC/IO% formamide at 52'C, in 2 x SSC at room temperature (RT). and incubated in an RNAse solution (100 pg/ml RNAse A) (Boehringer Mannheim; Mannheim, Germany) at 37°C as described (40) . After extensive washings, the cytospin preparations were then dehydrated and air-dried. The result was revealed by emulsion autoradiography (40).
To evaluate the specificity and reproducibility of the hybridization of the "'S-labeled anti-sense ERBB2 and MYC probes with the cell samples, the following control measures and precautions were taken: (a) the "S- Evaluation of the In Situ Hybridization Results. The cytospin preparations of tumor specimens were examined under immersion oil at x 1000 magnification and the numbers of grains overlying the cell profiles were determined over the entire field of vision. More specifically, the number of grains in at least 25 consecutive cells of each cytospin preparation hybridized with both anti-sense and sense probes was counted (40). Cells hybridized with a "'S-labeled anti-sense probe were considered positive if they contained more grains than any cell counted that had been hybridized with the corresponding sense probe. The data for each sample are presented as the percentage of cells positive for ERBB2 and MYC oncogene expression. The number of grains per cell is also stated for each of the positive tumor samples (after correcting the results by deducting the mean number of grains per cell obtained by hybridization with the corresponding "IS-labeled sense probe).
The cell samples were divided into four groups on the basis of the average number of grains per cell: negative ( -), <3 grains per cell; weakly positive ( + ), 3-6 grains per cell; moderately positive ( + + ), 6-10 grains per cell; strongly positive (+ + +), 10-30 grains per cell; and very strongly positive
Similar calculations were carried out for the tumor cell lines, the cytospin samples from the axillary lymph nodes, and the mature tissue neutrophils (found in some tumor samples).
Finally, because of the possibility of constitutive anti-sense oncogene transcription with MYC (43) . the number of grains per cell in the samples hybridized with "'S-labeled ERBB2 sense probe was compared with those hybridized with its MYC counterpart.
Flow Cytomeay. Tissue specimens were mechanically disaggregated with a surgical knife in PBS. The cell suspensions were allowed by sediment in conical 10-ml tubes for 5 min. and then the solutions were transferred into new tubes and centrifuged for 8 min at 400 x g. The cell pellets were suspended in PBS and the cell density was adjusted to 5 x lo6 cells/ml. The cells were processed and the nuclei were stained with propidium iodide as previously described by Vindelov et al. (44) . The specimens were analyzed with a FACScan flow cytometer (Becton-Dickinson; Mountain View, CA) equipped with CONSORT30 software.
Southem Blot Analysis. Tumor samples were kept at -7O'C until high molecular weight DNA for RFLP studies was prepared by standard techniques (45) . Ten pg of DNA was digested with Hind111 (New England Biolabs; Beverly, MA) and resolved by electrophoresis on 0.8% agarose gels (Seakem-LE Agarose; FMC Bioproducts, Rockland, ME) for 18 hr at 40 V.
DNAs were blotted onto 0.45-pm nitrocellulose membranes (BA 85; Schleicher & Schuell, Dassel, Germany). Membranes were hybridized with "' Plabeled ERBB2 gene cDNA probe @ W -4 3 6 -1 ; ATCC 59296), with MYC cDNA probe pML (46), or with INT2 genomic DNA probe SS6 (47) at 41' C with a hybridization mixture with 50% formamide. The posthybridization washes used were twice for 15 min with 1 x SSC, 0.1% SDS at RT, and three times for 15 min in 1 x SSC, 0.1% SDS at 60%. The signals were visualized by autoradiography after 1-14 days.
The copy number of ERBB2 and MYC was determined by comparing the signal intensity to a normal gene copy sample (leucocyte DNA) in each membrane. The amount of the DNA loaded to each lane was checked from the ethidium bromide-stained gels and ensured to be equivalent to the amount of the DNA of the leukocyte control.
The gene copy number of the amplified samples was measured more precisely by dilutional analysis (17), where a series of dilutions ofthe tumor DNA was subjected to Southern hybridization and the intensities of the detected bands were compared to the signal given by the normal gene copy sample. The tumor specimen was classified as amplified if the dilutional analysis indicated at least three genomic equivalents of the ERBB2 gene.
I m m u n o h i s t o c h e~. Immunostaining was done with the avidin-biotin complex method as described (40, 48) . Endogenous peroxidase was first blocked by immersing the sections in 0.1% H202 in absolute methanol and nonspecific binding was blocked by incubating the slides in 20% fetal calf serum. The sections were incubated for 1 hr at RT with the primary polyclonal sheep antibody (dilution 1:500) to the cytoplasmic domain of human ERBB2 oncoprotein (Cambridge Research Biochemicals; Cambridge, UK), followed by a secondary biotinylated anti-goat IgG (dilution 1:lOO) and the avidin-biotin complex (both from Dakopatts; Copenhagen, Denmark). According to the manufacturer, the ERBB2 antibody (OA-11-854) detects bands at 170 KD (thought to be a degradation product of the full length protein) and 185 KD on immunoblots of SK-BR-3 breast adenocarcinoma cell line membrane preparations, and works well on paraffin-embedded and fresh frozen tissue. The color was developed with diaminobenzidine and the sections were lightly counterstained with hematoxylin (40) . Negative controls for the immunostainings were carried out by substituting the primary antibody with non-immune rabbit semm or PBS.
The results were evaluated quantitatively as follows; -, no positive cells; 
ReSUltS

CytoLogy of Fine-needLe Aspiration Biopsies of Breast Tumors and Axdlary Lymph Nodes
Fine-needle aspiration of the tumors and lymph nodes gave an average yield of 3.4 x IO6 (range 0.5 x 106-6.2 x IO6) cells, with a viability of higher than 80%, as assessed by trypan blue exclusion. 
from the neoplastic cell population by their specific morphological features.
ERBB2 ana' MYC Expression in Cytological
Samples from Breast Tumors
The percentages of cells showing positive signals for ERBB2 and MYC, and the average numbers of grains per cell are presented in Tables 2 and 3, respectively. Eight of the 13 breast carcinomas showed ERBB2 expression, the percentages of expressing cells in the individual tumors ranging from 32 to 100%. There was only one case (Case 5 , Figure 3 ) in which 100% of the tumor cells expressed ERBB2, but strong or very strong expression could be observed in four cases, whereas the remaining four showed weak or moderate expression.
Table 3. MYC oncogene mRNA expression in fine-needle aspirates of breast tumors and corresponding results of gene amplzfication
The aspirates of the ductal carcinomas gave clusters and sheets of loosely attached neoplastic cells with increased nuclear size and irregular nuclear borders ( Figure I) , and the aspirate from the medullary carcinoma showed large, polygonal neoplastic cells with large nucleoli intermingled with reactive lymphocytes and plasma cells ( Figure 2) . The aspiration biopsy from the in situ lobular carcinoma showed small neoplastic cells with an increased nucleuskytoplasm ratio. The nucleoli were inconspicuous and the nuclear chromatin was delicate. In every case the cytospin preparations contained cells fulfilling criteria for malignancy.
Some of the cytospin samples contained lymphocytes and neutrophils among the tumor cells. These could easily be distinguished All the carcinomas studied showed MYC expression, affected cells ranging from 72 to 100% (Case 12, Figure 4) . MYC expression by all tumor cells was seen in nine cases. Altogether, 12 showed strong or very strong MYC expression and one moderate expression.
CO-expression of ERBB2 and MYC was found in eight cases, with a significantly higher expression of the MYC oncogene in the cases with ERBBZ expression than in those without (p = 0.019, two-tailed Student's t-test).
The Grade 111 infiltrative duct carcinomas showed six or more grains (the 35S-labeled ERBB2 probe) per cell, which was significantly more frequent than those of Grade 1-11 (p = 0.049), but there was no relationship between ERBB2 expression and tumor size, age of patient, or presence of metastases. No correlation could be observed between the GolGi, S, or GzlM fractions or tumor ploidy and ERBB2 expression.
The cells of the Grade 111 infiltrative ductal carcinomas hybridized with the 3JS-labeled MYC anti-sense probe showed 30 or more grains per cell, significantly more frequent than those of the Grade 1-11 duct carcinomas (p = 0.010). There was a weak, statistically non-significant correlation between the number of MYC grains per cell and tumor size in tumors of diameter <3 cm (r = 0.52857), revealed gene amplification corresponding to over four times the level obtained in normal cells in one out of the 13 samples studied (Figure 5) . This case (Case 5 ) also showed the highest number of grains per cell by in situ hybridization. A low level of MYC amplification (two-to threefold) was detected in two tumor specimens (Cases 8 and 9; data not shown), which also showed a high number of grains per cell by in situ hybridization analysis. Interestingly, no MYC gene amplification was observed in Cases 5 , 6, and 13, where the amount of grains per cell was substantially high.
In analysis by immunohistochemistry, four cases (Cases 5.6, 7, and 10) showed membrane-bound immunoreactivity for ERBB2 oncoprotein. In tumors in which only a subpopulation of the cells were positive, there was a clustering of cells to the same areas. Three of the ERBB2-positive cases (Cases 5,6, and 7) also showed increased mRNA synthesis. In these cases there was an association between the amount of positivity and the grain count per cell (see Table 2 ) . Interestingly, all cases showing amplification were Grade I11 tumors (p = 0.018 according to Fisher's exact probability test). They also studied the highest S-fraction in the tumor material studied.
but no correlation between MYC expression and the expression of metastases or the age of the patients. No correlation could be observed between the GolGl, S, or G2IM fractions or tumor ploidy (data not shown) and MYC expression.
ERBB2 and MYC fipression in T~~~~ cell ~i~~~
The percentages of ERBB2-and MYC-expressing tumor cells and the average numbers of grains per cell in the tumor cell lines are bresented in Table 4 .
All tumor cells expressed ERBB2 in two tumor cell lines (SK-B R -~, and 40% in one (HeLa). Two cell lines gave very strong signals for the ERBB2 (SK-BR-3, HT-29) ( Figure 6 ), one gave weak signals (HeLa), and two were negative (HL60, SK-LU-1) as deter-
Southern Blot Analysis and Immunohistochemistry
The results for Southern blot analysis and immunohistochemistry are summarized in Tables 2 and 3 , mined by the average number of grains per cell. Correspondingly, four cell lines (SK-BR-3, HeLa, HT-29, SK-LU-1) showed MYC expression in 100% of tumor cells and one (HL60) in 40%. Three cell lines gave very strong signals for MYC (SK-BR-3, HT-29. SK-LU-I) and two gave strong signals (HeLa, HL60) ( Figure 7 ). Three cell lines co-expressed ERBB2 and MYC (SK-BR-3, HeLa, HT-29).
The expression of ERBB2 and MYC was on average stronger in the tumor cell lines than in the breast tumors (mean average number of grains per cell 51.3 for ERBB2 and 58.5 for MYC in the tumor cell lines and 27.2 and 28.3 in the breast tumors, respectively).
A 60-100% reduction in the average number of grains per cell was seen when 30-min RNAse treatment was applied to some cell line samples before in situ hybridization with 3IS-labeled antisense ERBB2 or MYC probe. Repetition of some hybridization experiments with cell line samples gave similar reproducible results (data not shown).
. -
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.. ' -ERBB2 and MYC Expression in Cytospin Samples from Axzllary Lymph Nodes and in Neutrophils
No expression of ERBB2 was seen in the lymphocytes in the three axillary lymph node aspirates, but weak to moderate MYC expression (range 4.8-8.3 grains per cell) cold be observed for h4YC (Figure 8) . In contrast, no expression of either ERBB2 or MYC was observed in mature neutrophils from the tumor tissue ( Figure 9 ). 
Number of Grains per Cell with the 'JS-labeled ERBBZ and MYC Sense Probes
The mean number of grains per cell obtained by the ERBBZ sense probe in the tumors was 2.3 and that for the MYC probe 4.5, a significant difference according to Student's t-test (p = 0.05). The number of grains obtained by the ERBBZ sense probe was always lower than that obtained by the MYC sense probe. Similar results were also observed in the cell line and axillary lymph node samples.
Discussion
This study analyzed 13 consecutive breast carcinomas for expression of both ERBB2 and MYC proto-oncogenes. using fine-needle aspirates to test the usefulness of such material for this purpose.
Expression of the ERBBZ proto-oncogene was found in eight and MYC in all 13 cases. The results indicate a more pronounced expression of these proto-oncogenes in breast carcinoma than has becn reported previously (9.30.31). The reason for this finding may be partly due to the fact that the tumor specimens were processed and fixed as quickly as possible to minimize the time for the RNAcleaving enzymes to act. Another reason may concern the technique used. Grain counts can easily be performed on fine-needle aspirates , and there is considerably less background signal than in histological smions. Therefore. cases with weaker expression can more readily be detected in fine-needle aspirates of the tumors. Moreover, fineneedle aspiration a l l w samples to be taken from several areas of the tumor, which minimizes the possibility of sampling error. When the in situ hybridization results were compared with those of Southern blot analysis. elevated mRNA levels were observed for both ERBBZ and MYC in all cases in which there was amplification of the corresponding genes. However. with both proto-oncogenes considerably more cases showed enhanced mRNA synthesis than gene amplification results would suggest. One possible reason for this is that other mechanisms than gene amplification account for the elevated mRNA synthesis. This seems, in particular. to be true for MYC, which is known to act as a transcriptional factor and the expression ofwhich is usually elevated in highly proliferative cells (19). According to previous findings. amplification of ERBBZ and MYC genes is found in approximately the same proportion of breast carcinoma cases, whereas overexpression of MYC is an even more frequent event (9.30,31). The expression of MYC in other types of carcinoma has also been reported to be markedly high (6,25,28,49.50 ), e.g.. involving 72-100% of colon carcinoma cases (28. 49.50) . Interestingly, howevcr. gene amplification has been found in only a few cases of colon carcinoma (50) . also suggesting the dominance of some other molecular mechanism in this neoplasm.
Another reason for the discrepancy between in situ hybridization and gene amplification results could be due to the heterogeneity of tumor cell expression of these proto-oncogenes. If only a proportion of the tumor cell population contained an amplified gene. it could remain undetected by Southern blot analysis. In fact, in all our cases showing detectable gene amplification, all tumor cells showed elevated mRNA synthesis.
In immunohistochemistry, there was an association between the amount of ERBB2 mRNA synthesis and immunohistochemical ERBB2 positivity. However, not all cases with ERBBZ mRNA ex-pression were immunohistochemically positive. The reason for this is probably a sampling error, since ERBB2-positive cells were many times regionally distributed and only a small section of the whole tumor was analyzed by immunohistochemistry. On the other hand, the fine-needle aspirates were obtained from several areas of the tumor. However, it may be that in some cases with increased ERBB2 mRNA expression, no oncoprotein is produced. There was also one case in which no ERBB2 mRNA synthesis was found, even though the tumor expressed the oncoprotein (Case 10). This may be due to a sampling error; the needle had simply not penetrated an area in which such cells'were present.
When the ERBB2 and MYC mRNA in situ hybridization results were compared, it was seen that in all cases with ERBB2 expression there also was MYC expression. It is known that cytoplasmic and/or membrane-associated oncogenes may cooperate with nuclear oncogenes, and that activation of a single oncogene usually is not enough for neoplastic transformation (51) . The results may therefore suggest that ERBBZ could cooperate with MYC in the evolution of breast carcinoma. Conversely, the cases with no ERBB2 expression had a significantly lower expression of MYC. ERBB2 is homologous in structure to the EGF receptor, and its protein product is located on the cell surface, indicating that the oncoprotein may function as a membrane receptor (2). Moreover, it has been shown that EGF may activate MYC expression (20). It is therefore possible that the increased transcription of ERBB2 mRNA and the synthesis of the corresponding oncoprotein via the stimulus of some unknown growth factor may lead to enhanced MYC activity.
The finding of an association between the histological grade of the breast carcinomas and the expression of ERBB2 and MYC is in accordance with the results obtained by some other investiga tors (8,14) . An association with the degree of MYC expression and a high tumor grade has also been found in renal carcinomas (26) and cholangiocarcinomas (6). There was no association between ERBBZ or MYC expression and the presence of metastases, the size of the tumors, or the age of the patients. This is in contrast to the results obtained by some other authors, who describe an association between the expression of MYC and the presence of metastases (9) or the age of the patient (30). It may be that the association between these variables and the expression of MYC is not so strong that it would be readily observable in our material.
Of the tumor cell lines analyzed, SK-BR-3 has been shown to express both ERBB2 and MYC (36) and HL60 MYC (37). Our results regarding these two cell lines are in accordance with these previous observations. The tumor cell lines expressed both ERBB2 and MYC more strongly than did the breast tumors, possibly because the tumor cell line populations are selected and probably more homogeneous. The existence of co-expression between ERBB2 and MYC in non-breast carcinoma cell lines may point to the fact that putative cooperation between these two oncogenes may also be present in other neoplasms.
There is some evidence for constitutive anti-sense MYC transcription (43), and in accordance with this we found a significantly higher number of grains per cell by hybridization with the 3JSlabeled MYC sense probe than with the corresponding ERBB2 sense probe. The number of grains per cell with both sense probes was low, however, and consequently the putative constitutive anti-sense MYC transcription did not affect the results to any appreciable degree.
In conclusion, our results show that in situ hybridization complemented with fine-needle aspiration is a sensitive method to detect ERBB2 and MYC proto-oncogene expression in breast carcinoma. In fact, fine-needle aspiration may be more applicable in clinical cases because of the accessibility and the ease with which the samples can be taken, as compared with ordinary histology.
